Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 8—August 2013

Genotype GI.6 Norovirus, United States, 2010–2012

Article Metrics
citations of this article
EID Journal Metrics on Scopus
Eyal LeshemComments to Author , Leslie Barclay, Mary Wikswo, Everardo Vega, Nicole Gregoricus, Umesh D. Parashar, Jan Vinjé, and Aron J. Hall
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Cite This Article


We report an increase in the proportion of genotype GI.6 norovirus outbreaks in the United States from 1.4% in 2010 to 7.7% in 2012 (p<0.001). Compared with non-GI.6 outbreaks, GI.6 outbreaks were characterized by summer seasonality, foodborne transmission, and non–health care settings.

Noroviruses are the leading cause of epidemic gastroenteritis, including foodborne outbreaks, and a major cause of sporadic gastroenteritis in the United States (13). Hospitalizations and deaths associated with norovirus infection occur most frequently among elderly persons, young children, and immunocompromised persons (2,4). Noroviruses can be divided into at least 5 genogroups (GI–GV) and at least 35 genotypes. Human disease is primarily caused by GI and GII noroviruses, and most norovirus outbreaks are caused by genotype GII.4 viruses (5). During the past decade, new GII.4 strains have emerged every 2–3 years, replacing previously predominant GII.4 strains (68). GI noroviruses are relatively uncommon, and systematic descriptions of GI outbreak epidemiology and characteristics are scarce (9). Before 2010, genotype GI.6 noroviruses were rarely reported in the United States; <5 GI.6 outbreaks were reported each year to the Centers for Disease Control and Prevention (J. Vinjé, pers. comm.). We report the emergence of GI.6 norovirus as a cause of outbreaks in the United States and discuss its effect on public health.

The Study

Since 2009, the Centers for Disease Control and Prevention has operated 2 surveillance systems for norovirus outbreaks in the United States: CaliciNet and the National Outbreak Reporting System (NORS). CaliciNet is an electronic laboratory surveillance network that collects information on genetic sequences of noroviruses implicated in outbreaks (5). As of 2011, public health laboratories in all 50 states are either certified members of CaliciNet or submit norovirus-positive specimens to 1 of 5 regional CaliciNet Outbreak Support Centers. NORS is an electronic surveillance system for reporting all enteric disease outbreaks, regardless of etiology or mode of transmission (3). Data reported in NORS include outbreak characteristics, demographics, symptoms, implicated exposures, clinical outcomes, and etiologies

Figure 1

Thumbnail of Phylogenetic typing results for GI.6 noroviruses, United States, 2010–2012. Representative outbreak nucleotide sequences were genotyped by region D (5). Sequences were downloaded, trimmed, and analyzed as described (5). In brief, a 3-parameter model, TPM1, with equal frequencies and invariable sites was run in PhyML 3.0 ( as determined by jModel test by using the corrected Akaike information criterion. The best of 5 random trees was used to

Figure 1. . Phylogenetic typing results for GI.6 noroviruses, United States, 2010–2012. Representative outbreak nucleotide sequences were genotyped by region D (5). Sequences were downloaded, trimmed, and analyzed as described (<>

We identified GI.6 outbreaks with a first illness onset date during January 1, 2010–December 31, 2012, from CaliciNet and linked them to NORS by using unique outbreak identification numbers. Supplemental information derived from NORS included mode of transmission, outbreak setting, and patients’ demographic features and clinical outcomes. State health departments were queried about outbreaks that could not be linked to NORS and requested to provide such supplemental information directly. Annual variation in GI.6 outbreaks was assessed by χ2 test for trend, and GI.6 seasonality was identified on the basis of visual examination of trends over time and compared with non-GI.6 seasonality by using Mid-P exact test. Norovirus-positive specimens were typed by using region D sequence analysis (5) (Figure 1).

Figure 2

Thumbnail of GI.6 norovirus outbreaks detected by CaliciNet, United States, 2010–2012.

Figure 2. . GI.6 norovirus outbreaks reported through CaliciNet, United States, 2010–2012.

A total of 141 GI.6 outbreaks in 27 states were identified over the 3-year study period. During 2010 and 2011, causitive strains for 12 (1.4%) of 879 and 30 (3.9%) of 760 outbreaks, respectively, reported through CaliciNet were typed as GI.6. During 2012, 99 (7.7%) of the 1,279 norovirus outbreaks reported through CaliciNet tested positive for GI.6, indicating a significant increase in genotype GI.6 outbreaks over the 3-year period (Figure 2; p<0.001). During 2010–2012, a total of 66 (46.8%) of 141 GI.6 outbreaks occurred during April–July, compared with 382 (13.8%) 2,777 non-GI.6 outbreaks (p<0.001).

The most commonly identified mode of transmission was person-to-person, which occurred in 81 (57.4%) GI.6 outbreaks (Table 1). Foodborne transmission was more frequent among GI.6 than among non-GI.6 outbreaks reported to CaliciNet during the same period (rate ratio [RR] 1.77, 95% CI 1.25–2.51). Waterborne transmission also was more common in GI.6 outbreaks; the 2 waterborne GI.6 outbreaks occurred during June and July.

The most commonly reported outbreak setting was long-term–care facilities, representing 51 (36.2%) outbreaks. GI.6 outbreaks were reported less frequently in health care–related settings (hospitals and long-term–care facilities) than were non-GI.6 outbreaks (36.9% vs. 65.7%; RR 0.56, 95% CI 0.45–0.70).

GI.6 outbreaks accounted for 4,375 reported illnesses, with a median of 22 (range 2–178) reported illnesses per outbreak. Supplementary demographic and clinical outcome information was available for 66 (46.8%) outbreaks, comprising 2,220 reported illnesses. Data on hospitalization and death were provided for most (>79.0%) of these illnesses; other patient characteristics were reported less frequently (Table 2). Most (52.2%) patients were male, and 22.2% were >75 years of age; 1.4% of GI.6 outbreak patients were hospitalized, and 0.2% died.

Molecular typing data demonstrated that GI.6 viruses can be grouped into 2 clusters (Figure 1), with earlier outbreaks occurring deeper in the tree. One of the earliest occurring outbreaks in cluster A (2011-OB-274) occurred in Tennessee in February 2011 and involved a conference with 8,000 attendees and 143 reportedcases in persons from 12 states.


We detected an increase in GI.6 outbreaks in the United States since 2010, with peak activity during summer 2012. Summer seasonality, foodborne transmission, and non–health care settings characterized GI.6 outbreaks, compared with non-GI.6 outbreaks reported through CaliciNet. Noroviruses are the most common cause of gastroenteritis outbreaks, and although GI.6 noroviruses remain responsible for a relatively small proportion of all reported norovirus outbreaks, they have unique characteristics and public health implications that differ from those of more common genotypes.

During 2010–2012, genotype GII.4 consistently represented most (70%) of the norovirus outbreaks reported through CaliciNet (J. Vinjé, pers. comm.). Therefore, the unique characteristics of GI.6 outbreaks described here primarily reflect differences between GI.6 and GII.4 noroviruses.

The absolute number of outbreaks and the proportion of outbreaks caused by GI.6 noroviruses peaked during April–July. This summer seasonal pattern contrasts with the overall winter seasonality of norovirus outbreaks driven primarily by winter surges in GII.4 norovirus activity (3,68). A study of GI norovirus outbreaks in Australia demonstrated peak outbreak activity during their summer months, compared with a late winter peak for GII norovirus outbreaks (9). In a previous study in the United States, the highest number of GI outbreaks occurred during April–May, but no apparent seasonality was noted (7).

Comparisons of hospitalization and death rates reported during GI.6 outbreaks with those observed in recent outbreaks caused by the emergent GII.4 Sydney strain (8) indicated slightly lower rates of hospitalization (1.4% vs. 2.2%; RR 0.63, 95% CI 0.39–1.02) and death (0.2% vs. 0.4%; RR 0.44, 95% CI 0.12–1.62). This observation may reflect a previously described association of GII.4 outbreaks with severe outcomes (10).

Region D typing data presented in this study indicates 2 clusters of GI.6 noroviruses in the United States. In February 2011, an outbreak among persons from multiple states occurred at a conference in Tennessee; this outbreak might have been a dissemination event for GI.6 activity because outbreaks of genetically related GI.6 noroviruses belonging to the same cluster occurred later in several of the states in which the conference attendees resided. However, more sequence information from the complete open reading frame (ORF2) or the hypervariable region of the protruding domain (P2) is needed to confirm possible links among the outbreaks (5).

Our study has several limitations. These include incomplete linkage of outbreaks reported in CaliciNet to outbreak reports in NORS and the resulting gaps in data on transmission mode and setting, as well as low rates of reporting of demographic characteristics, symptoms, and clinical outcomes. These limitations preclude direct comparison of GI.6 outbreak characteristics with characteristics of outbreaks linked to other genotypes. Efforts to improve reporting rates and integration between CaliciNet and NORS are under way (8).

Noroviruses are a diverse group of pathogens with varied characteristics. Continued surveillance for norovirus outbreaks through CaliciNet and NORS will enable further assessment of the public health implications and significance of emergence of relatively rare noroviruses, such as GI.6. Proper hand hygiene, environmental disinfection, and isolation of ill persons remain the mainstays of norovirus prevention and control (11).

Dr Leshem is an Epidemic Intelligence Service officer with the Viral Gastroenteritis Team in the Division of Viral Diseases of the National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. His research interests include viral gastroenteritis, vaccine-preventable diseases, and travel and tropical medicine.



We gratefully acknowledge the efforts of state and local health departments in the investigation and reporting of these outbreaks. We also thank LaTonia Richardson, Kelly Walsh, and Virginia Roberts for assistance with NORS data extraction and linkage with CaliciNet.



  1. Hall  AJ, Eisenbart  VG, Etingue  AL, Gould  LH, Lopman  BA, Parashar  UD. Epidemiology of foodborne norovirus outbreaks, United States, 2001–2008. Emerg Infect Dis. 2012;18:156673 and. DOIPubMedGoogle Scholar
  2. Hall  AJ, Lopman  BA, Patel  MM, Gastañaduy  PA, Vinjé  J. Norovirus disease in the United States. Emerg Infect Dis. 2013;19: 11981205.DOIPubMedGoogle Scholar
  3. Hall  AJ, Wikswo  ME, Manikonda  K, Roberts  VA, Yoder  JS, Gould  LH. Acute gastroenteritis surveillance through the National Outbreak Reporting System, United States. Emerg Infect Dis. 2013;19: 13059.
  4. Bok  K, Green  KY. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med. 2012;367:212632. DOIPubMedGoogle Scholar
  5. Vega  E, Barclay  L, Gregoricus  N, Williams  K, Lee  D, Vinje  J. Novel surveillance network for norovirus gastroenteritis outbreaks, United States. Emerg Infect Dis. 2011;17:138995 .PubMedGoogle Scholar
  6. Yen  C, Wikswo  ME, Lopman  BA, Vinje  J, Parashar  UD, Hall  AJ. Impact of an emergent norovirus variant in 2009 on norovirus outbreak activity in the United States. Clin Infect Dis. 2011;53:56871. DOIPubMedGoogle Scholar
  7. Zheng  DP, Widdowson  MA, Glass  RI, Vinje  J. Molecular epidemiology of genogroup II-genotype 4 noroviruses in the United States between 1994 and 2006. J Clin Microbiol. 2010;48:16877. DOIPubMedGoogle Scholar
  8. Leshem  E, Wikswo  ME, Barclay  L, Salehi  E, Storm  W, Brandt  E, Effects and clinical significance of GII.4 Sydney norovirus, United States, 2012–2013. Emerg Infect Dis. 2013;19:12318.
  9. Bruggink  LD, Oluwatoyin  O, Sameer  R, Witlox  KJ, Marshall  JA. Molecular and epidemiological features of gastroenteritis outbreaks involving genogroup I norovirus in Victoria, Australia, 2002–2010. J Med Virol. 2012;84:143748. DOIPubMedGoogle Scholar
  10. Desai  R, Hembree  CD, Handel  A, Matthews  JE, Dickey  BW, McDonald  S, Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review. Clin Infect Dis. 2012;55:18993. DOIPubMedGoogle Scholar
  11. Centers for Disease Control and Prevention. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm Rep. 2011;60(RR-3):118 .PubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid1908.130445

Table of Contents – Volume 19, Number 8—August 2013

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Eyal Leshem, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop A34 Atlanta, GA 30333, USA

Send To

10000 character(s) remaining.


Page created: July 19, 2013
Page updated: July 19, 2013
Page reviewed: July 19, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.